Carboxyethylpyrrole Oxidative Protein Modifications Stimulate Neovascularization: Implications for Age-Related Macular Degeneration

Choroidal neovascularization (CNV), the advanced stage of agerelated macular degeneration (AMD), accounts for > 80% of vision loss in AMD. Carboxyethylpyrrole (CEP) protein modifications, uniquely generated from oxidation of docosahexaenoate-containing lipids, are more abundant in Bruch's me...

Full description

Saved in:
Bibliographic Details
Published inProceedings of the National Academy of Sciences - PNAS Vol. 103; no. 36; pp. 13480 - 13484
Main Authors Ebrahem, Quteba, Renganathan, Kutralanathan, Sears, Jonathan, Vasanji, Amit, Gu, Xiaorong, Lu, Liang, Salomon, Robert G., Crabb, John W., Anand-Apte, Bela
Format Journal Article
LanguageEnglish
Published United States National Academy of Sciences 05.09.2006
National Acad Sciences
Subjects
Adducts
Aged, 80 and over
Allantois - blood supply
Angiogenesis
Animals
Antibodies
Biological Sciences
Bruch Membrane - chemistry
Cell Culture Techniques
Cell Line
Cells, Cultured
Chick Embryo
Child
Chorioallantoic membrane
Chorion - blood supply
Choroidal Neovascularization - etiology
Choroidal Neovascularization - metabolism
Cornea
Dose-Response Relationship, Drug
Eyes & eyesight
Health savings accounts
Humans
Laser Coagulation
Lasers
Macular degeneration
Macular Degeneration - metabolism
Membranes
Mice
Mice, Inbred C57BL
Middle Aged
Neovascularization, Physiologic
Oxidation
Oxidation-Reduction
Pigment Epithelium of Eye - cytology
Pigment Epithelium of Eye - drug effects
Pigment Epithelium of Eye - metabolism
Proteins
Pyrroles - chemistry
Pyrroles - metabolism
Pyrroles - pharmacology
Rats
Rats, Sprague-Dawley
Secretion
Serum Albumin - chemistry
Serum albumins
Vascular Endothelial Growth Factor A - analysis
Vascular Endothelial Growth Factor A - metabolism
Online AccessGet full text

Cover

Abstract Choroidal neovascularization (CNV), the advanced stage of agerelated macular degeneration (AMD), accounts for > 80% of vision loss in AMD. Carboxyethylpyrrole (CEP) protein modifications, uniquely generated from oxidation of docosahexaenoate-containing lipids, are more abundant in Bruch's membrane from AMD eyes. We tested the hypothesis that CEP protein adducts stimulate angiogenesis and possibly contribute to CNV in AMD. Human serum albumin (HSA) or acetyl-Gly-Lys-O-methyl ester (dipeptide) were chemically modified to yield CEP-modified HSA (CEP-HSA) or CEP-dipeptide. The in vivo angiogenic properties of CEP-HSA and CEP-dipeptide were demonstrated by using the chick chorioallantoic membrane and rat corneal micropocket assays. Low picomole amounts of CEP-HSA and CEP-dipeptide stimulated neovascularization. Monoclonal anti-CEP antibody neutralized limbal vessel growth stimulated by CEP-HSA, whereas anti-VEGF antibody was found to only partially neutralize vessel growth. Subretinal injections of CEP-modified mouse serum albumin exacerbated laser-induced CNV in mice. In vitro treatments of human retinal pigment epithelial cells with CEP-dipeptide or CEP-HSA did not induce increased VEGF secretion. Overall, these results suggest that CEP-induced angiogenesis utilizes VEGF-independent pathways and that anti-CEP therapeutic modalities might be of value in limiting CNV in AMD.
AbstractList Choroidal neovascularization (CNV), the advanced stage of age-related macular degeneration (AMD), accounts for >80% of vision loss in AMD. Carboxyethylpyrrole (CEP) protein modifications, uniquely generated from oxidation of docosahexaenoate-containing lipids, are more abundant in Bruch’s membrane from AMD eyes. We tested the hypothesis that CEP protein adducts stimulate angiogenesis and possibly contribute to CNV in AMD. Human serum albumin (HSA) or acetyl-Gly-Lys- O -methyl ester (dipeptide) were chemically modified to yield CEP-modified HSA (CEP-HSA) or CEP-dipeptide. The in vivo angiogenic properties of CEP-HSA and CEP-dipeptide were demonstrated by using the chick chorioallantoic membrane and rat corneal micropocket assays. Low picomole amounts of CEP-HSA and CEP-dipeptide stimulated neovascularization. Monoclonal anti-CEP antibody neutralized limbal vessel growth stimulated by CEP-HSA, whereas anti-VEGF antibody was found to only partially neutralize vessel growth. Subretinal injections of CEP-modified mouse serum albumin exacerbated laser-induced CNV in mice. In vitro treatments of human retinal pigment epithelial cells with CEP-dipeptide or CEP-HSA did not induce increased VEGF secretion. Overall, these results suggest that CEP-induced angiogenesis utilizes VEGF-independent pathways and that anti-CEP therapeutic modalities might be of value in limiting CNV in AMD.
Choroidal neovascularization (CNV), the advanced stage of agerelated macular degeneration (AMD), accounts for > 80% of vision loss in AMD. Carboxyethylpyrrole (CEP) protein modifications, uniquely generated from oxidation of docosahexaenoate-containing lipids, are more abundant in Bruch's membrane from AMD eyes. We tested the hypothesis that CEP protein adducts stimulate angiogenesis and possibly contribute to CNV in AMD. Human serum albumin (HSA) or acetyl-Gly-Lys-O-methyl ester (dipeptide) were chemically modified to yield CEP-modified HSA (CEP-HSA) or CEP-dipeptide. The in vivo angiogenic properties of CEP-HSA and CEP-dipeptide were demonstrated by using the chick chorioallantoic membrane and rat corneal micropocket assays. Low picomole amounts of CEP-HSA and CEP-dipeptide stimulated neovascularization. Monoclonal anti-CEP antibody neutralized limbal vessel growth stimulated by CEP-HSA, whereas anti-VEGF antibody was found to only partially neutralize vessel growth. Subretinal injections of CEP-modified mouse serum albumin exacerbated laser-induced CNV in mice. In vitro treatments of human retinal pigment epithelial cells with CEP-dipeptide or CEP-HSA did not induce increased VEGF secretion. Overall, these results suggest that CEP-induced angiogenesis utilizes VEGF-independent pathways and that anti-CEP therapeutic modalities might be of value in limiting CNV in AMD.
Choroidal neovascularization (CNV), the advanced stage of age-related macular degeneration (AMD), accounts for >80% of vision loss in AMD. Carboxyethylpyrrole (CEP) protein modifications, uniquely generated from oxidation of docosahexaenoate-containing lipids, are more abundant in Bruch's membrane from AMD eyes. We tested the hypothesis that CEP protein adducts stimulate angiogenesis and possibly contribute to CNV in AMD. Human serum albumin (HSA) or acetyl-Gly-Lys-O-methyl ester (dipeptide) were chemically modified to yield CEP-modified HSA (CEP-HSA) or CEP-dipeptide. The in vivo angiogenic properties of CEP-HSA and CEP-dipeptide were demonstrated by using the chick chorioallantoic membrane and rat corneal micropocket assays. Low picomole amounts of CEP-HSA and CEP-dipeptide stimulated neovascularization. Monoclonal anti-CEP antibody neutralized limbal vessel growth stimulated by CEP-HSA, whereas anti-VEGF antibody was found to only partially neutralize vessel growth. Subretinal injections of CEP-modified mouse serum albumin exacerbated laser-induced CNV in mice. In vitro treatments of human retinal pigment epithelial cells with CEP-dipeptide or CEP-HSA did not induce increased VEGF secretion. Overall, these results suggest that CEP-induced angiogenesis utilizes VEGF-independent pathways and that anti-CEP therapeutic modalities might be of value in limiting CNV in AMD.
Choroidal neovascularization (CNV), the advanced stage of age-related macular degeneration (AMD), accounts for >80% of vision loss in AMD. Carboxyethylpyrrole (CEP) protein modifications, uniquely generated from oxidation of docosahexaenoate-containing lipids, are more abundant in Bruch’s membrane from AMD eyes. We tested the hypothesis that CEP protein adducts stimulate angiogenesis and possibly contribute to CNV in AMD. Human serum albumin (HSA) or acetyl-Gly-Lys- O -methyl ester (dipeptide) were chemically modified to yield CEP-modified HSA (CEP-HSA) or CEP-dipeptide. The in vivo angiogenic properties of CEP-HSA and CEP-dipeptide were demonstrated by using the chick chorioallantoic membrane and rat corneal micropocket assays. Low picomole amounts of CEP-HSA and CEP-dipeptide stimulated neovascularization. Monoclonal anti-CEP antibody neutralized limbal vessel growth stimulated by CEP-HSA, whereas anti-VEGF antibody was found to only partially neutralize vessel growth. Subretinal injections of CEP-modified mouse serum albumin exacerbated laser-induced CNV in mice. In vitro treatments of human retinal pigment epithelial cells with CEP-dipeptide or CEP-HSA did not induce increased VEGF secretion. Overall, these results suggest that CEP-induced angiogenesis utilizes VEGF-independent pathways and that anti-CEP therapeutic modalities might be of value in limiting CNV in AMD. oxidation
Choroidal neovascularization (CNV), the advanced stage of age-related macular degeneration (AMD), accounts for >80% of vision loss in AMD. Carboxyethylpyrrole (CEP) protein modifications, uniquely generated from oxidation of docosahexaenoate-containing lipids, are more abundant in Bruch's membrane from AMD eyes. We tested the hypothesis that CEP protein adducts stimulate angiogenesis and possibly contribute to CNV in AMD. Human serum albumin (HSA) or acetyl-Gly-Lys-O-methyl ester (dipeptide) were chemically modified to yield CEP-modified HSA (CEP-HSA) or CEP-dipeptide. The in vivo angiogenic properties of CEP-HSA and CEP-dipeptide were demonstrated by using the chick chorioallantoic membrane and rat corneal micropocket assays. Low picomole amounts of CEP-HSA and CEP-dipeptide stimulated neovascularization. Monoclonal anti-CEP antibody neutralized limbal vessel growth stimulated by CEP-HSA, whereas anti-VEGF antibody was found to only partially neutralize vessel growth. Subretinal injections of CEP-modified mouse serum albumin exacerbated laser-induced CNV in mice. In vitro treatments of human retinal pigment epithelial cells with CEP-dipeptide or CEP-HSA did not induce increased VEGF secretion. Overall, these results suggest that CEP-induced angiogenesis utilizes VEGF-independent pathways and that anti-CEP therapeutic modalities might be of value in limiting CNV in AMD. [PUBLICATION ABSTRACT]
Author Vasanji, Amit
Gu, Xiaorong
Anand-Apte, Bela
Sears, Jonathan
Lu, Liang
Salomon, Robert G.
Renganathan, Kutralanathan
Ebrahem, Quteba
Crabb, John W.
Author_xml – sequence: 1
  givenname: Quteba
  surname: Ebrahem
  fullname: Ebrahem, Quteba
– sequence: 2
  givenname: Kutralanathan
  surname: Renganathan
  fullname: Renganathan, Kutralanathan
– sequence: 3
  givenname: Jonathan
  surname: Sears
  fullname: Sears, Jonathan
– sequence: 4
  givenname: Amit
  surname: Vasanji
  fullname: Vasanji, Amit
– sequence: 5
  givenname: Xiaorong
  surname: Gu
  fullname: Gu, Xiaorong
– sequence: 6
  givenname: Liang
  surname: Lu
  fullname: Lu, Liang
– sequence: 7
  givenname: Robert G.
  surname: Salomon
  fullname: Salomon, Robert G.
– sequence: 8
  givenname: John W.
  surname: Crabb
  fullname: Crabb, John W.
– sequence: 9
  givenname: Bela
  surname: Anand-Apte
  fullname: Anand-Apte, Bela
BackLink https://www.ncbi.nlm.nih.gov/pubmed/16938854$$D View this record in MEDLINE/PubMed
BookMark eNqF0c1v0zAUAHALDbFucOYEirhxyPZsx4nDAWkqX5M2hvg4W47z3LlK4-C4Vbvr_nGStmrhxMmy3-99WO-MnLS-RUJeUrigUPDLrtX9BeRAhWAU-BMyoVDSNM9KOCETAFakMmPZKTnr-zkAlELCM3JK85JLKbIJeZzqUPn1BuP9puk2IfgGk7u1q3V0K0y-BR_Rtcmtr511Znj0bZ_8iG6xbHTE5Cv6le7NcAnuYRt9l1wvuuZArQ_J1QzT7zj6OrnVW5x8wBm2GLbqOXlqddPji_15Tn59-vhz-iW9uft8Pb26SY3IRUxLTa02NEdZGSwY05TWuWAyQy6tKaWtOS8qxriVdZHxykClrZCGCQHUVsDPyftd3W5ZLbA22MagG9UFt9Bho7x26t9I6-7VzK8UFXlJpRwKvNkXCP73Evuo5n4Z2mFmxYDyTLKCDehyh0zwfR_QHhpQUOPS1Lg0dVzakPH677mOfr-lASR7MGYey3HFczX2Hf_29j9E2WXTRFzHwb7a2XkffThgDiBAUsb_AJOPu78
CitedBy_id crossref_primary_10_1021_tx200093m
crossref_primary_10_1017_S146239941000164X
crossref_primary_10_1155_2014_413150
crossref_primary_10_1016_j_bbamem_2012_01_018
crossref_primary_10_1371_journal_pone_0111472
crossref_primary_10_1371_journal_pone_0203816
crossref_primary_10_1161_CIRCRESAHA_112_274241
crossref_primary_10_2353_ajpath_2009_080927
crossref_primary_10_3390_ijms19103176
crossref_primary_10_4155_fmc_12_202
crossref_primary_10_1016_j_rechem_2023_100995
crossref_primary_10_1074_mcp_M900127_MCP200
crossref_primary_10_1007_s00109_013_1007_3
crossref_primary_10_1016_j_preteyeres_2013_07_003
crossref_primary_10_1016_j_exer_2018_09_012
crossref_primary_10_1038_nature09421
crossref_primary_10_1194_jlr_M700598_JLR200
crossref_primary_10_5318_wjo_v4_i3_29
crossref_primary_10_1021_tx200206v
crossref_primary_10_1016_j_exer_2006_09_008
crossref_primary_10_12659_MSM_889887
crossref_primary_10_1016_j_preteyeres_2010_02_002
crossref_primary_10_1021_ja0689785
crossref_primary_10_1039_D2FO02788G
crossref_primary_10_1021_tx500216a
crossref_primary_10_1371_journal_pone_0067263
crossref_primary_10_1021_acs_chemrestox_6b00304
crossref_primary_10_3390_ijms25094779
crossref_primary_10_3390_antiox12122111
crossref_primary_10_3389_fimmu_2022_867082
crossref_primary_10_1161_CIRCRESAHA_112_275388
crossref_primary_10_3390_jcm3041542
crossref_primary_10_1016_S1734_1140_13_71005_3
crossref_primary_10_1007_s00394_018_1771_5
crossref_primary_10_1038_nrg2717
crossref_primary_10_1021_tx9002484
crossref_primary_10_1021_acs_chemrestox_5b00001
crossref_primary_10_1038_s41598_018_27479_x
crossref_primary_10_1371_journal_pone_0076325
crossref_primary_10_3390_antiox8100447
crossref_primary_10_1016_j_survophthal_2017_05_003
crossref_primary_10_1111_ceo_13121
crossref_primary_10_1021_acs_chemrestox_6b00153
crossref_primary_10_1074_jbc_M113_498832
crossref_primary_10_1021_acs_chemrestox_6b00152
crossref_primary_10_1016_j_bmc_2009_09_009
crossref_primary_10_1016_j_ejpb_2015_02_011
crossref_primary_10_3390_ijms13032717
crossref_primary_10_1016_j_exer_2010_03_003
crossref_primary_10_1096_fj_07_9509com
crossref_primary_10_1021_acs_chemrestox_6b00233
crossref_primary_10_1016_j_preteyeres_2014_11_005
crossref_primary_10_1111_jpi_12430
crossref_primary_10_1161_CIRCRESAHA_117_305925
crossref_primary_10_1016_j_freeradbiomed_2020_03_017
crossref_primary_10_1016_j_preteyeres_2016_04_003
crossref_primary_10_1182_blood_2013_09_512749
crossref_primary_10_3109_02713683_2015_1067326
crossref_primary_10_1038_s41598_023_47721_5
crossref_primary_10_1111_acel_13579
crossref_primary_10_1371_journal_pone_0098864
crossref_primary_10_1021_acsnano_7b00429
crossref_primary_10_1007_s00417_008_0789_4
crossref_primary_10_1155_2019_2304018
crossref_primary_10_1007_s00726_010_0778_x
crossref_primary_10_1016_j_exer_2016_12_006
crossref_primary_10_1016_j_bbagen_2009_04_016
crossref_primary_10_1097_ICU_0b013e32833866c8
crossref_primary_10_1074_mcp_M700525_MCP200
crossref_primary_10_1074_mcp_M800453_MCP200
crossref_primary_10_1074_mcp_M900523_MCP200
crossref_primary_10_1371_journal_pone_0145323
crossref_primary_10_1002_jrs_2011
crossref_primary_10_1016_j_bbalip_2016_09_022
crossref_primary_10_1016_j_jaut_2009_09_003
crossref_primary_10_1021_tx900204z
crossref_primary_10_1002_ajoc_201600565
Cites_doi 10.1016/S0002-9440(10)65753-7
10.1038/ng1750
10.1056/NEJMoa042760
10.1073/pnas.0502819102
10.1073/pnas.0503015102
10.1007/s00417-002-0568-6
10.1001/archopht.1991.01080090056026
10.1002/jcla.1860070503
10.1006/bbrc.1997.7036
10.1126/science.1110189
10.1016/S1537-1891(02)00170-2
10.1021/jo026721t
10.1006/mvre.1994.1003
10.1073/pnas.0501536102
10.1074/jbc.M205924200
10.1073/pnas.222551899
10.1074/jbc.M203318200
10.1126/science.1110359
10.1006/mvre.2001.2371
10.1074/jbc.M305460200
10.1001/archopht.1991.01080090066027
10.1001/jama.1996.03540140029022
10.1016/0163-7827(83)90004-8
10.4049/jimmunol.174.1.491
10.1016/S0161-6420(13)38010-5
10.1016/S0039-6257(00)00140-5
10.1021/tx970112c
10.1126/science.1109557
10.1021/jo0105383
10.1001/archopht.116.12.1629
10.1016/S0008-4182(05)80078-X
10.1001/archopht.119.10.1417
10.1016/j.ophtha.2005.01.043
10.1002/1097-4652(200009)184:3<301::AID-JCP3>3.0.CO;2-H
ContentType Journal Article
Copyright Copyright 2006 National Academy of Sciences of the United States of America
Copyright National Academy of Sciences Sep 5, 2006
2006 by The National Academy of Sciences of the USA 2006
Copyright_xml – notice: Copyright 2006 National Academy of Sciences of the United States of America
– notice: Copyright National Academy of Sciences Sep 5, 2006
– notice: 2006 by The National Academy of Sciences of the USA 2006
DBID CGR
CUY
CVF
ECM
EIF
NPM
AAYXX
CITATION
7QG
7QL
7QP
7QR
7SN
7SS
7T5
7TK
7TM
7TO
7U9
8FD
C1K
FR3
H94
M7N
P64
RC3
5PM
DOI 10.1073/pnas.0601552103
DatabaseName Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
CrossRef
Animal Behavior Abstracts
Bacteriology Abstracts (Microbiology B)
Calcium & Calcified Tissue Abstracts
Chemoreception Abstracts
Ecology Abstracts
Entomology Abstracts (Full archive)
Immunology Abstracts
Neurosciences Abstracts
Nucleic Acids Abstracts
Oncogenes and Growth Factors Abstracts
Virology and AIDS Abstracts
Technology Research Database
Environmental Sciences and Pollution Management
Engineering Research Database
AIDS and Cancer Research Abstracts
Algology Mycology and Protozoology Abstracts (Microbiology C)
Biotechnology and BioEngineering Abstracts
Genetics Abstracts
PubMed Central (Full Participant titles)
DatabaseTitle MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
CrossRef
Virology and AIDS Abstracts
Oncogenes and Growth Factors Abstracts
Technology Research Database
Nucleic Acids Abstracts
Ecology Abstracts
Neurosciences Abstracts
Biotechnology and BioEngineering Abstracts
Environmental Sciences and Pollution Management
Entomology Abstracts
Genetics Abstracts
Animal Behavior Abstracts
Bacteriology Abstracts (Microbiology B)
Algology Mycology and Protozoology Abstracts (Microbiology C)
AIDS and Cancer Research Abstracts
Chemoreception Abstracts
Immunology Abstracts
Engineering Research Database
Calcium & Calcified Tissue Abstracts
DatabaseTitleList CrossRef

MEDLINE


Virology and AIDS Abstracts
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Sciences (General)
EISSN 1091-6490
EndPage 13484
ExternalDocumentID 1151393481
10_1073_pnas_0601552103
16938854
103_36_13480
30050812
Genre Comparative Study
Research Support, Non-U.S. Gov't
Journal Article
Research Support, N.I.H., Extramural
GrantInformation_xml – fundername: NEI NIH HHS
  grantid: EY06603
– fundername: NEI NIH HHS
  grantid: R01 EY006603
– fundername: NEI NIH HHS
  grantid: F32 EY006603
– fundername: NIGMS NIH HHS
  grantid: R01 GM021249
– fundername: NEI NIH HHS
  grantid: R24 EY015638
– fundername: NEI NIH HHS
  grantid: R01 EY014239
– fundername: NEI NIH HHS
  grantid: R01 EY016490
– fundername: NEI NIH HHS
  grantid: EY016490
– fundername: NEI NIH HHS
  grantid: EY014239
– fundername: NCI NIH HHS
  grantid: R01 CA106415
GroupedDBID ---
-DZ
-~X
.55
.GJ
0R~
123
29P
2AX
2FS
2WC
3O-
4.4
53G
5RE
5VS
79B
85S
AACGO
AAFWJ
AANCE
AAYJJ
ABBHK
ABOCM
ABPLY
ABPPZ
ABTLG
ABXSQ
ABZEH
ACGOD
ACIWK
ACNCT
ACPRK
ADULT
ADZLD
AENEX
AEUPB
AEXZC
AFFNX
AFOSN
AFRAH
ALMA_UNASSIGNED_HOLDINGS
AQVQM
ASUFR
AS~
BKOMP
CS3
D0L
DCCCD
DIK
DNJUQ
DOOOF
DU5
DWIUU
E3Z
EBS
EJD
F20
F5P
FRP
GX1
HH5
HQ3
HTVGU
HYE
JAAYA
JBMMH
JENOY
JHFFW
JKQEH
JLS
JLXEF
JPM
JSG
JSODD
JST
KQ8
L7B
LU7
MVM
N9A
N~3
O9-
OK1
P-O
PNE
PQQKQ
R.V
RHF
RHI
RNA
RNS
RPM
RXW
SA0
SJN
TAE
TN5
UKR
VQA
W8F
WH7
WHG
WOQ
WOW
X7M
XFK
XSW
Y6R
YBH
YKV
YSK
ZA5
ZCA
ZCG
~02
~KM
-
02
0R
1AW
55
AAPBV
ABFLS
ABPTK
ADACO
AJYGW
AS
DZ
GJ
KM
PQEST
X
XHC
ADACV
CGR
CUY
CVF
ECM
EIF
H13
IPSME
NPM
AAYXX
CITATION
7QG
7QL
7QP
7QR
7SN
7SS
7T5
7TK
7TM
7TO
7U9
8FD
C1K
FR3
H94
M7N
P64
RC3
5PM
ID FETCH-LOGICAL-c565t-9a1fac16e8bce722a11d65284e38fc98fd337b223f8d743bc0baf58c25501fb03
IEDL.DBID RPM
ISSN 0027-8424
IngestDate Tue Sep 17 20:47:37 EDT 2024
Thu Oct 10 15:34:47 EDT 2024
Fri Aug 23 01:50:52 EDT 2024
Sat Nov 02 12:17:54 EDT 2024
Wed Nov 11 00:29:59 EST 2020
Thu May 30 08:49:40 EDT 2019
Fri Feb 02 07:05:36 EST 2024
IsDoiOpenAccess false
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 36
Language English
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c565t-9a1fac16e8bce722a11d65284e38fc98fd337b223f8d743bc0baf58c25501fb03
Notes Edited by Mark T. Keating, Novartis Institutes for Biomedical Research, Cambridge, MA, and approved July 17, 2006
Q.E. and K.R. contributed equally to this work.
Author contributions: Q.E., J.W.C., and B.A.-A. designed research; Q.E., K.R., J.S., and L.L. performed research; X.G. and R.G.S. contributed new reagents/analytic tools; Q.E., K.R., A.V., J.W.C., and B.A.-A. analyzed data; and J.W.C. and B.A.-A. wrote the paper.
OpenAccessLink https://doi.org/10.1073/pnas.0601552103
PMID 16938854
PQID 201348272
PQPubID 42026
PageCount 5
ParticipantIDs pubmedcentral_primary_oai_pubmedcentral_nih_gov_1569188
crossref_primary_10_1073_pnas_0601552103
proquest_journals_201348272
pnas_primary_103_36_13480
pnas_primary_103_36_13480_fulltext
pubmed_primary_16938854
jstor_primary_30050812
ProviderPackageCode RNA
PNE
PublicationCentury 2000
PublicationDate 2006-09-05
PublicationDateYYYYMMDD 2006-09-05
PublicationDate_xml – month: 09
  year: 2006
  text: 2006-09-05
  day: 05
PublicationDecade 2000
PublicationPlace United States
PublicationPlace_xml – name: United States
– name: Washington
PublicationTitle Proceedings of the National Academy of Sciences - PNAS
PublicationTitleAlternate Proc Natl Acad Sci U S A
PublicationYear 2006
Publisher National Academy of Sciences
National Acad Sciences
Publisher_xml – name: National Academy of Sciences
– name: National Acad Sciences
References Proc Natl Acad Sci U S A. 2006 Oct 17;103(42):15722
e_1_3_4_3_2
e_1_3_4_2_2
e_1_3_4_1_2
e_1_3_4_9_2
e_1_3_4_8_2
e_1_3_4_7_2
e_1_3_4_6_2
e_1_3_4_4_2
e_1_3_4_22_2
e_1_3_4_23_2
Winkler B. S. (e_1_3_4_5_2) 1999; 5
e_1_3_4_21_2
e_1_3_4_26_2
e_1_3_4_27_2
e_1_3_4_24_2
e_1_3_4_25_2
Handa J. T. (e_1_3_4_28_2) 1999; 40
e_1_3_4_29_2
Hoffmann S. (e_1_3_4_20_2) 2000; 41
e_1_3_4_30_2
e_1_3_4_11_2
e_1_3_4_34_2
e_1_3_4_12_2
e_1_3_4_33_2
e_1_3_4_32_2
e_1_3_4_10_2
e_1_3_4_31_2
e_1_3_4_15_2
e_1_3_4_38_2
e_1_3_4_16_2
e_1_3_4_37_2
e_1_3_4_13_2
e_1_3_4_14_2
e_1_3_4_35_2
e_1_3_4_19_2
e_1_3_4_17_2
e_1_3_4_18_2
Crabb J. W. (e_1_3_4_36_2) 1997
References_xml – ident: e_1_3_4_38_2
  doi: 10.1016/S0002-9440(10)65753-7
– ident: e_1_3_4_9_2
  doi: 10.1038/ng1750
– ident: e_1_3_4_33_2
  doi: 10.1056/NEJMoa042760
– ident: e_1_3_4_13_2
  doi: 10.1073/pnas.0502819102
– ident: e_1_3_4_15_2
  doi: 10.1073/pnas.0503015102
– ident: e_1_3_4_31_2
  doi: 10.1007/s00417-002-0568-6
– ident: e_1_3_4_2_2
  doi: 10.1001/archopht.1991.01080090056026
– ident: e_1_3_4_29_2
  doi: 10.1002/jcla.1860070503
– ident: e_1_3_4_19_2
  doi: 10.1006/bbrc.1997.7036
– ident: e_1_3_4_8_2
  doi: 10.1126/science.1110189
– ident: e_1_3_4_24_2
  doi: 10.1016/S1537-1891(02)00170-2
– ident: e_1_3_4_26_2
  doi: 10.1021/jo026721t
– ident: e_1_3_4_37_2
  doi: 10.1006/mvre.1994.1003
– ident: e_1_3_4_10_2
  doi: 10.1073/pnas.0501536102
– ident: e_1_3_4_22_2
  doi: 10.1074/jbc.M205924200
– ident: e_1_3_4_16_2
  doi: 10.1073/pnas.222551899
– ident: e_1_3_4_23_2
  doi: 10.1074/jbc.M203318200
– ident: e_1_3_4_11_2
  doi: 10.1126/science.1110359
– ident: e_1_3_4_18_2
  doi: 10.1006/mvre.2001.2371
– ident: e_1_3_4_17_2
  doi: 10.1074/jbc.M305460200
– ident: e_1_3_4_1_2
  doi: 10.1001/archopht.1991.01080090066027
– volume: 5
  start-page: 32
  year: 1999
  ident: e_1_3_4_5_2
  publication-title: Mol. Vis.
  contributor:
    fullname: Winkler B. S.
– ident: e_1_3_4_6_2
  doi: 10.1001/jama.1996.03540140029022
– ident: e_1_3_4_27_2
  doi: 10.1016/0163-7827(83)90004-8
– ident: e_1_3_4_14_2
  doi: 10.4049/jimmunol.174.1.491
– ident: e_1_3_4_32_2
  doi: 10.1016/S0161-6420(13)38010-5
– ident: e_1_3_4_4_2
  doi: 10.1016/S0039-6257(00)00140-5
– ident: e_1_3_4_21_2
  doi: 10.1021/tx970112c
– ident: e_1_3_4_12_2
  doi: 10.1126/science.1109557
– ident: e_1_3_4_25_2
  doi: 10.1021/jo0105383
– volume: 40
  start-page: 775
  year: 1999
  ident: e_1_3_4_28_2
  publication-title: Invest. Ophthalmol. Vis. Sci.
  contributor:
    fullname: Handa J. T.
– ident: e_1_3_4_30_2
  doi: 10.1001/archopht.116.12.1629
– ident: e_1_3_4_34_2
  doi: 10.1016/S0008-4182(05)80078-X
– ident: e_1_3_4_7_2
  doi: 10.1001/archopht.119.10.1417
– ident: e_1_3_4_35_2
  doi: 10.1016/j.ophtha.2005.01.043
– ident: e_1_3_4_3_2
  doi: 10.1002/1097-4652(200009)184:3<301::AID-JCP3>3.0.CO;2-H
– volume-title: Amino Acid Analysis
  year: 1997
  ident: e_1_3_4_36_2
  contributor:
    fullname: Crabb J. W.
– volume: 41
  start-page: 2389
  year: 2000
  ident: e_1_3_4_20_2
  publication-title: Invest. Ophthalmol. Vis. Sci.
  contributor:
    fullname: Hoffmann S.
SSID ssj0009580
Score 2.2482827
Snippet Choroidal neovascularization (CNV), the advanced stage of agerelated macular degeneration (AMD), accounts for > 80% of vision loss in AMD. Carboxyethylpyrrole...
Choroidal neovascularization (CNV), the advanced stage of age-related macular degeneration (AMD), accounts for >80% of vision loss in AMD. Carboxyethylpyrrole...
SourceID pubmedcentral
proquest
crossref
pubmed
pnas
jstor
SourceType Open Access Repository
Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 13480
SubjectTerms Adducts
Aged, 80 and over
Allantois - blood supply
Angiogenesis
Animals
Antibodies
Biological Sciences
Bruch Membrane - chemistry
Cell Culture Techniques
Cell Line
Cells, Cultured
Chick Embryo
Child
Chorioallantoic membrane
Chorion - blood supply
Choroidal Neovascularization - etiology
Choroidal Neovascularization - metabolism
Cornea
Dose-Response Relationship, Drug
Eyes & eyesight
Health savings accounts
Humans
Laser Coagulation
Lasers
Macular degeneration
Macular Degeneration - metabolism
Membranes
Mice
Mice, Inbred C57BL
Middle Aged
Neovascularization, Physiologic
Oxidation
Oxidation-Reduction
Pigment Epithelium of Eye - cytology
Pigment Epithelium of Eye - drug effects
Pigment Epithelium of Eye - metabolism
Proteins
Pyrroles - chemistry
Pyrroles - metabolism
Pyrroles - pharmacology
Rats
Rats, Sprague-Dawley
Secretion
Serum Albumin - chemistry
Serum albumins
Vascular Endothelial Growth Factor A - analysis
Vascular Endothelial Growth Factor A - metabolism
Title Carboxyethylpyrrole Oxidative Protein Modifications Stimulate Neovascularization: Implications for Age-Related Macular Degeneration
URI https://www.jstor.org/stable/30050812
http://www.pnas.org/content/103/36/13480.abstract
https://www.ncbi.nlm.nih.gov/pubmed/16938854
https://www.proquest.com/docview/201348272
https://pubmed.ncbi.nlm.nih.gov/PMC1569188
Volume 103
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Nb9QwEB21PXFBFCikBWQhDuWQXSeOE4cbWlEVJBAHKvVm-RNWarKr3UVqz_xxxo6z20Vw4eyxZWXG9hvnzTPAGyNKWyNOzdvSuxwhtcF9kNG8ZIYqjCBnfWT5fqkvr6pP1_z6APhYCxNJ-0bPJ_1NN-nnPyK3ctmZ6cgTm379PMOcoy0wczuEQwzQMUXfKu2Koe6kxO23KqtRz6dh02Wv1pMgQMLx0KLxCZ26ZULwau9UGoiJQe0U7f-GPP8kUN47kS4ewcMEJcn7YcrHcOD6x3CcFuuanCdF6bdP4NdMrfTi9s6hV26Wd6tAKSSL27mNqt8kajXMe9ItbCAODXd4BNd-F972cqR3W8Jqqtp8Rz7eY6ITBL4E96U8FsY4SzoVjYl13-McgtVTuLr48G12mafXF3KDIG-Tt6rwyhS1E9q4pixVUdia42nmmPCmFd4y1mhEF15YhCHaUK08FwZzFFp4TdkJHPWL3j0H4oRoG93USjtf1Zq3mOUh0tGV9ZQ5yjM4H7--XA4iGzL-HG-YDD6QO59lcBK9s7ULcvsIa8oMsmi6688kq2XBKkEzeP3PNukTySaDs9HRMq3jtUR4FNR_Ghz-2eDy3SApdDJo9oJhaxCEu_dbMJ6jgHeK39P_7nkGD4aroDan_AUcbVY_3UsERxv9Ki6G34I_EMU
link.rule.ids 230,315,730,783,787,888,27938,27939,53806,53808
linkProvider National Library of Medicine
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Nb9QwEB2VcoALtEAhtICFOJRDsk6cD6e3akW1hbbi0KLerPirrGiyq92tBFz544ydZLdbwQHOHjuJZjx-4zw_A7xTPNE54tSwTKwJEVIrzIOMhglTtMIIMtp6lu9ZPrpIP15mlxuQ9WdhPGlfyXHUXNdRM_7quZXTWg16ntjg8-kQa44yxsrtHtzH-Urzvkhfau3y9uRJggk4TdJe0adgg2lTzSMnQZLhskX9JTp5yTjP0rV1qaUmOr1TtP8T9rxLoby1Jh09hi_917RUlG_RzUJG6ucdocd__twteNShVHLYNm_DhmmewHaXB-ZkvxOrfv8Ufg2rmcTHG3T49fTHzLEVyeT7WHtBceJlIMYNqSfacZLa7UGCaaV214YZ0pglF7Y7EHpAjm-R3AliaoIpL_RnbowmdeWNiTZX_h2c1TO4OPpwPhyF3cUOoUL8uAjLKraVinPDpTJFklRxrPMMF0rDuFUlt5qxQiJwsVwjwpGKyspmXGH5Q2MrKduBzWbSmBdADOdlIYu8ksamucxKLCARRMlUW8oMzQLY790qpq1-h_D_3QsmnHPFKhgC2PFuX9o5JX9ETEkAgTdd9WeC5SJmKacBvP1rm7AdfyeA3T6CRJci5gKRlxMWKnD4520srQbpYjKAYi3KlgZOE3y9BWPHa4N3sfLyv3u-gQej89MTcXJ89mkXHrY7TmVIsz3YXMxuzCvEYAv52s-434JzMsM
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwEB5BkRAXoEBLKA8LcSiHZJ04D4cbWli1PKoeqFRxseIXrGiy0e5WAq78ccZOso8KLj1nbNnyeOYb5_NngFeKJzpHnBqWiTUhQmqFcZDRMGGKVuhBRlvP8j3Jj87SD-fZ-cZTX560r-Q0ai7qqJl-99zKtlajgSc2Ov08xpqjjLFya7Ud3YRbuGcpHwr1ld4u726fJBiE0yQdVH0KNmqbahE5GZIMUxf1D-nkJeM8S7dyU0dPdJqnaP8v_HmVRrmRlyb34Oswo46O8iO6XMpI_b4i9nitKd-Huz1aJW87k124YZoHsNvHgwU57EWrXz-EP-NqLnEIBhf-ov01d6xFMvs51V5YnHg5iGlD6pl23KTumJBgeKnd82GGNGbFie0vhr4hxxtkd4LYmmDoC_3dG6NJXXljos03PwZn9QjOJu-_jI_C_oGHUCGOXIZlFdtKxbnhUpkiSao41nmGCdMwblXJrWaskAhgLNeIdKSisrIZV1gG0dhKyvZgp5k15jEQw3lZyCKvpLFpLrMSC0kEUzLVljJDswAOh6UVbafjIfz_94IJt8Bi7RAB7PmlX9k5RX9ETkkAgTddt2eC5SJmKacBvPzvN2F7Hk8AB4MXiT5ULAQiMCcwVGD3-50_rTvp_TKAYsvTVgZOG3z7C_qP1wjv_eXJtVu-gNun7ybi0_HJxwO40x08lSHNnsLOcn5pniEUW8rnftP9Bfm5NUM
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Carboxyethylpyrrole+oxidative+protein+modifications+stimulate+neovascularization%3A+Implications+for+age-related+macular+degeneration&rft.jtitle=Proceedings+of+the+National+Academy+of+Sciences+-+PNAS&rft.au=Ebrahem%2C+Quteba&rft.au=Renganathan%2C+Kutralanathan&rft.au=Sears%2C+Jonathan&rft.au=Vasanji%2C+Amit&rft.date=2006-09-05&rft.issn=0027-8424&rft.eissn=1091-6490&rft.volume=103&rft.issue=36&rft.spage=13480&rft.epage=13484&rft_id=info:doi/10.1073%2Fpnas.0601552103&rft.externalDBID=n%2Fa&rft.externalDocID=10_1073_pnas_0601552103
thumbnail_m http://utb.summon.serialssolutions.com/2.0.0/image/custom?url=http%3A%2F%2Fwww.pnas.org%2Fcontent%2F103%2F36.cover.gif
thumbnail_s http://utb.summon.serialssolutions.com/2.0.0/image/custom?url=http%3A%2F%2Fwww.pnas.org%2Fcontent%2F103%2F36.cover.gif